Margin upside building into H2 We cut EBITDA by 9-4% for '25e-'27e Trading at ~22x '26e EV/EBITDA F...
Q2'25e organic sales growth of 45% y-o-y We raise '25e paying users by 2% FVR of SEK 30-45 reiterate...
Taaleri’s continuing earnings of EUR 10.6m increased by 6% y/y and were 8% above our estimate.
Redeye updates in Better Collective ahead of Q2-results (due 20 August after market close) where we ...
Redeye updates its view on Genovis' following a Q2 2025 report falling slightly short of our estimat...
Raute’s margins impress, while extended low orders pose big earnings headwinds, yet multiples remain...
As Q2 numbers had already been pre-released, yesterday's report (12 August) did not contain any surp...
Redeye comments on Xspray’s out-licensing of certain patents covering the commercialization of a das...
Redeye takes a more positive view regarding q.beyond following the Q2 report, showing improved profi...
The company’s adjusted EBITDA was EUR 3.1m (pre-announced) in Q2.
Redeye's view of Genovis Q2 report is balanced, sales were largely in line but profitability was sof...
Redeye provides an initial take on the Q2 2025 report from Scandinavian ChemoTech.
Alisa Bank’s H1 financials were as expected weak but still slightly below our estimates.
Raute’s EUR 43.8m Q2 top line came in clearly below our estimate, yet the EUR 6.
Marimekko reports its Q2 figures on 14th of August.
Market conditions remain unfavourable for Aurdel Septon divestment carries largest impact on estimat...
Net sales were below our expectations and adjusted EBITDA was above for Q2.
Redeye comments on Alzinova’s announcement of having submitted an IND application and a Fast Track D...
Group net sales was EUR 29.5m in Q2 (Nordea EUR 30.
Vi inleder bevakning på mResell, en ledande svensk aktör inom re-commerce som specialiserar sig på r...